PEERLESS Study
Brief description of study
The FlowTriever Retrieval/Aspiration System (referred to as “FlowTriever”) is an FDA-cleared device designed to treat pulmonary embolism (PE). A PE is a blood clot trapped in your lung. The FlowTriever is used to remove the clot by pulling it into a catheter so that the clot can be removed from your body.
Catheter directed thrombolysis (“CDT”) devices are catheters placed close to the pulmonary embolism that slowly release a medication to dissolve the clot.
Some CDT devices also use ultrasound to help the medication dissolve the clot. The CDT devices used in this study are all FDA-cleared and your physician will determine which CDT system is best for you. Participants will be invited to the PEERLESS Study because their doctor may use either FlowTriever or CDT to treat the patients pulmonary embolism.
The purpose of the study is to compare how FlowTriever and CDT work when treating pulmonary embolism, and to collect data about your pulmonary embolism treatment and follow-up.
The study will collect data on demographics, comorbidities, details from the PE diagnosis and treatment, and clinical outcomes through 30-day follow up.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
pulmonary embolism
-
Age: - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 850399
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
